Prestige Consumer Healthcare Inc. (PBH)
NYSE NYSE Primary 
XFRA 
Premium Brands: Long Climb To $10 Billion
Premium Brands continues steady mid-single-digit organic growth, with Q2 revenue up 12.4% year-over-year, but faces margin pressure from higher interest and investment cycle. The company's high leverage (Debt/EBITDA ~4x) and ongoing M&A strategy weigh on net profit and cash flow, despite improved free cash flow this quarter. Long-term targets are ambitious ($10B revenue, $1–1.2B EBITDA by FY 2027), but current valuation and debt levels limit upside versus broader market returns.
Prestige Consumer Healthcare Inc. (PBH) Q1 2026 Earnings Call Transcript
Prestige Consumer Healthcare Inc. (NYSE:PBH ) Q1 2026 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Christine Sacco - CFO & COO Philip David Terpolilli - Director of Investor Relations Ronald M. Lombardi - Chairman, President & CEO Conference Call Participants Anthony Chester Lebiedzinski - Sidoti & Company, LLC Douglas Matthai Lane - Water Tower Research LLC Glenn West - William Blair & Company L.L.C.
Prestige Consumer Healthcare (PBH) Misses Q1 Earnings and Revenue Estimates
Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $0.95 per share, missing the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.9 per share a year ago.
Why Prestige Consumer Healthcare (PBH) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
PBH vs. SYK: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
PBH vs. ESLOY: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks presents investors with the better value opportunity right now?
Prestige Consumer Healthcare Inc. (PBH) Q4 2025 Earnings Call Transcript
Prestige Consumer Healthcare Inc. (NYSE:PBH ) Q4 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Phil Terpolilli – Vice President, Investor Relations and Treasury Ron Lombardi – Chairman, President and Chief Executive Officer Christine Sacco – Chief Financial Officer and Chief Operating Officer Conference Call Participants Rupesh Parikh – Oppenheimer Susan Anderson – Canaccord Keith Devas – Jefferies Glenn West – William Blair Anthony Lebiedzinski – Sidoti & Company Doug Lane – Water Tower Research Operator Good day, and thank you for standing by. Welcome to the Prestige Consumer Healthcare's Fourth Quarter 2025 Earnings Conference Call.
PBH or ABT: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
PBH vs. SYK: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
Prestige Consumer Gains 17.1% in a Year: What's Driving the Stock?
PBH's shares rise on the back of its portfolio of consumer brands and focus on core strategies to achieve long-term success.
Should You Consider Retaining PBH Stock in Your Portfolio Now?
Investors remain optimistic about Prestige Consumer due to its strong focus on brand building and strategic acquisition.
PBH or BSX: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
